Department of Pharmacology and Physiology, College of Medicine, Drexel University, Philadelphia, PA 19102, United States.
Department of Psychiatry, New York University Langone Medical Center, New York University, New York, and the Nathan Kline Institute, Orangeburg, NY, United States.
J Neurosci Methods. 2019 May 1;319:7-15. doi: 10.1016/j.jneumeth.2018.10.032. Epub 2018 Oct 24.
It is now widely recognized that endogenous, picomolar concentrations of the 42 amino acid long peptide, amyloid-β (Aβ) is secreted under normal physiological conditions and exerts important functional activity throughout neuronal intracellular compartments. Transgenic animal models that overexpress Aβ and its precursor, amyloid precursor protein (APP), have not provided predictive value in testing new treatments for Alzheimer's disease (AD), resulting in failed clinical trials. While these results are discouraging, they underscore the need to understand the physiological roles of Aβ and APP under normal conditions as well as at early pre- symptomatic stages of AD. New method: We describe the use of acrolein-perfusion in immunoelectron microscopy in combination with novel antibodies directed against endogenous murine Aβ and APP fragments to study abnormalities in the endolysosomal system at early stages of disease. The specific requirements, limitations and advantages of novel antibodies directed against human and murine Aβ, APP and APP fragments are discussed as well as parameters for ultrastructural analysis of endolysosomal compartments.
Novel antibodies and a detailed protocol for immunoelectron microscopy using acrolein as a fixative are described. Acrolein is shown to preserve intraneuronal Aβ species, as opposed to paraformaldehyde fixed tissue, which primarily preserves membrane bound species. Comparison with existing method(s): Technology sensitive enough to detect endogenous Aβ under physiological conditions has not been widely available. We describe a number of novel and highly sensitive antibodies have recently been developed that may facilitate the analysis of endogenous Aβ.
Using novel and highly specific antibodies in combination with electron microscopy may reveal important information about the timing of aberrant protein accumulation, as well as the progression of abnormalities in the endolysosomal systems that sort and clear these peptides.
现在人们广泛认为,在正常生理条件下,内源性、皮摩尔浓度的 42 个氨基酸长的肽,即淀粉样β(Aβ)被分泌,并在神经元细胞内室中发挥重要的功能活性。过度表达 Aβ及其前体淀粉样前体蛋白(APP)的转基因动物模型在测试阿尔茨海默病(AD)的新治疗方法方面没有提供预测价值,导致临床试验失败。虽然这些结果令人沮丧,但它们强调了需要了解 Aβ和 APP 在正常条件下以及在 AD 的早期症状前阶段的生理作用。新方法:我们描述了使用丙烯醛灌注在免疫电子显微镜中结合针对内源性鼠 Aβ和 APP 片段的新型抗体的方法,以研究疾病早期阶段内溶酶体系统的异常。还讨论了针对人 Aβ、APP 和 APP 片段的新型抗体的具体要求、局限性和优点,以及内溶酶体隔室的超微结构分析参数。
描述了新型抗体和使用丙烯醛作为固定剂的免疫电子显微镜详细方案。与使用多聚甲醛固定组织的方法相反,丙烯醛被证明可以保留神经元内的 Aβ 物质,而多聚甲醛固定组织主要保留膜结合的物质。与现有方法比较:在生理条件下检测内源性 Aβ 的技术尚未广泛可用。我们描述了一些最近开发的新型和高度敏感的抗体,它们可能有助于内源性 Aβ 的分析。
使用新型和高度特异性抗体结合电子显微镜可能揭示关于异常蛋白积累的时间以及内溶酶体系统异常进展的重要信息,这些异常会对这些肽进行分类和清除。